The 2025 AHA guidelines replace the blanket “treat all adults over 65 at 130/80” standard with a 10-year cardiovascular risk-guided framework. Roughly 1 in 10 older Americans with stage 1 hypertension no longer meet criteria for immediate medication under the updated approach.
Professional Impact
- Risk-guided prescribing now replaces age-and-number thresholds for stage 1 hypertension (130-139/80-89 mmHg) in adults over 65
- Overtreatment risks are real: dizziness, falls, fractures, and acute kidney injury are documented concerns, particularly in frail older adults and those with CKD
- Undertreatment risk is equally real: critics warn that time-pressured primary care visits may produce a “don’t treat” default rather than careful risk stratification
- About 40% of older adults with hypertension may benefit from a treatment approach that weighs overall cardiovascular risk profile rather than blood pressure numbers alone
Practice Applications
- Incorporate 10-year CVD risk calculation into hypertension treatment decisions for patients 65 to 79 with stage 1 readings
- Prioritize intensive treatment for patients with diabetes, CKD, or multiple cardiometabolic risk factors regardless of blood pressure tier
- Document your risk stratification reasoning when deferring medication in lower-risk older adults to support clinical decision-making and reduce liability exposure
- Reassess current patients on antihypertensives who may have been initiated under the 2017 blanket criteria
More on Hypertension & Blood Pressure
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS